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Sumrrlary 
A dominant gene carried in certain inbred mouse strains confers susceptibility to tumors induced 
by polyoma  virus.  This  gene,  designated  Pyv  s,  was  defined  in  crosses  between  the  highly 
susceptible C3H/BiDa strain and the highly resistant but H-2k-identical C57BR/cdJ strain.  The 
resistance of C57BR/cdJ mice is overcome by irradiation,  indicating  an immunological basis. 
In F1  x  C57BR/cdJ backcross mice,  tumor  susceptibility cosegregates with Mtv-7,  a mouse 
mammary  tumor  provirus  carried  by the  C3H/BiDa  strain.  This  suggests  that  Pyv  s might 
encode the Mtv-7 superantigen (SAG) and abrogate polyoma tumor immunosurveillance through 
elimination of T cells bearing specific VB domains. DNA typing of 110 backcross mice showed 
no  evidence  of recombination  between Pyv  s  and  Mtv-7.  Strongly  biased  usage  of VB6  by 
polyoma virus-specific CD8 § cytotoxic T  lymphocytes in C57BR/cdJ mice implicates T  cells 
bearing this Mtv-7 SAG-reactive VB domain as critical anti-polyoma tumor effector cells in vivo. 
These results indicate identity between Pyv  s and Mtv-7 sag, and demonstrate a novel mechanism 
of inherited susceptibility to virus-induced tumors based on effects of an endogenous superantigen 
on the host's T  cell repertoire. 
D 
evelopment of neoplastic disease requires that a cell first 
become transformed and then be able to evade the host's 
immune system. The importance of an intact immune system 
in preventing overt neoplastic disease is highlighted  by the 
increased incidence of malignancies in immunocompromised 
individuals (1). Tumor cell variants that escape immunosur- 
veillance  can emerge in immunocompetent  hosts,  and var- 
ious mechanisms of immune evasion at the level of the tumor 
celt have been documented (2-6).  In principle,  transformed 
cells expressing neoantigens might also escape immune rec- 
ognition due to a hole in the host's T  cell repertoire.  Such 
a phenomenon involving defective tumor-specific T  cell re- 
sponses in  otherwise immunocompetent  hosts has,  to our 
knowledge, not been reported. Results presented here on sus- 
ceptibility of the mouse to polyoma virus-induced  tumors 
provide the first evidence for a genetically dominant mecha- 
nism  of this  kind. 
Polyoma virus is a potent oncogenic agent capable of in- 
ducing multiple solid tumors in the mouse, its natural host 
(7, 8). For over three decades the polyoma-mouse system has 
served as a model for investigations of immune responses to 
virus-induced cancers. Early studies using neonatally thymec- 
tomized mice, nude mice, and adoptive transfer of polyoma 
virus-immune splenocytes showed that resistance  to polyoma 
tumors is mediated by T cells (9-11). Although the primary 
effector T  cell mediating resistance to polyoma tumors has 
not been fully defined,  CD8 § CTLs specific for syngeneic 
cells expressing polyoma tumor-specific transplantation  an- 
tigen(s) (TSTAs) 1 are known to be induced by polyoma in- 
fection (12). 
MHC molecules as well as products of non-MHC genes 
control susceptibility to polyoma-induced tumors. In crosses 
between MHC-nonidentical strains differing in susceptibility, 
resistance is inherited in a dominant or codominant manner 
determined largely by the MHC difference itself (9, 13). In- 
terestingly,  the opposite pattern of inheritance  is seen in crosses 
between MHC-identical  (H-2  k)  mice where  susceptibility 
rather than  resistance  is dominant  (13).  In crosses between 
the highly susceptible C3H/BiDa mouse and the highly resis- 
tant but MHC-identical  C57BK/cdJ mouse,  susceptibility 
is conferred by a single autosomal dominant gene which we 
have designated Pyv  s (14). 
Evidence presented here strongly suggests that Pyv  s is the 
1Abbreviations used in this paper: LT, large T  protein; MT, middle T 
protein; Mtv, mouse mammary tumor virus; PyvS, polyoma tumor 
susceptibility  gene; SAG, superantigen; SSR, simple  sequence  repeat; TFI, 
tumor frequency  index; TIL, tumor-infiltrating lymphocyte;  TSTA, tumor- 
specific transplantation antigen. 
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tumor provirus Mtv-7. Mouse mammary tumor virus (Mtv) 
superantigens (SAG) are type II transmembrane glycoproteins 
(15, 16) encoded by an open reading frame in the YLTK of 
the provirus (17, 18). Like bacterial superantigens, Mtv SAGs 
associate with class II MHC molecules and bind to the vari- 
able domain of the fl-chain (V~) of the TCR (19). A poly- 
morphic region in the carboxy terminus of Mtv SAGs deter- 
mines its VB domain specificity (20).  As self-proteins,  Mtv 
SAGs alter the peripheral T cell repertoire by intrathymic de- 
letion of VB-reactive  T cells (21-24). Results of genetic and 
immunological experiments indicate Pyv  s is Mtv-7 sag  and 
induces susceptibility to the oncogenic effects of the virus 
by deleting precursors of polyoma TSTA-specific  T  cells. 
Materials and Methods 
Mice.  C57BR/cdJ,  C3H/HeJ, CBA/J, CBA/CaJ, and RF/J 
mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME). C3H/BiDa mice were purchased from the Frederick Cancer 
Research and Development Center of the National Cancer Insti- 
tute (Frederick, MD). Newborn mice (<18 h of age) were inocu- 
lated intraperitoneally with molecularly  cloned and plaque-purified 
polyoma virus, and examined for tumors as described (8,  14). 
6-wk-old C57BR/cdJ female mice received 800 or 900 rads of 
"y-radiation  in a Gammacell 40 (Atomic Energy of Canada, Ltd., 
Ottawa, Canada), and, 24 h later, were inoculated intraperitoneally 
with virus. A cell line was established from a salivary  tumor arising 
in one of these mice. This cell line expressed full-length small T 
and middle T (MT) proteins, a truncated large T (LT) protein (25), 
and no polyoma VP1 capsid protein. 
Polyoma tumors carried by serial passage in normal C57BR/cdJ 
mice were finely minced and injected subcutaneously in 0.25-ml 
vol into 6-8-wk-old C57BR/cdJ mice that had been inoculated at 
birth with polyoma virus. 
Cytofluorometric Analysis.  Viable  mononuclear cells from spleens 
or lymph nodes were isolated on LSM (Organon Teknika, Rock- 
ville, MD). Spleen cells were subsequently enriched for T cells on 
nylon wool columns as described (26). Cells were indirectly stained 
with FITC-conjugated goat anti-hamster IgG or FITC-conjugated 
goat anti-rat IgG F(ab')2 secondary antibodies (Caltag Laborato- 
ties, South San Francisco,  CA) and culture supernatants of the fol- 
lowing hybridomas: B20.6, recognizing V32 (from B. Malissen, 
Centre d'Immunologie de Marseille-Luminy,  France); KJ25, recog- 
nizing VB3 (from P. Marrack andJ. Kappler, National  Jewish Center 
for Immunology  and Respiratory Medicine, Denver, CO); 44-22-1, 
recognizing V36  (from H. Hengartner,  Institute  of Pathology, 
University  Hospital, Zurich, Switzerland); TR310, recognizing  V37 
(from C. Okada, Stanford University School of Medicine, Stan- 
ford, CA); R14-2, recognizing V314 (from D. Raulet, University 
of California, Berkeley,  CA); and H57-597, recognizing o~3-TCR 
(from R. Kubo, National Jewish Center for Immunology  and Re- 
spiratory Medicine, Denver, CO). PE-conjugated anti-CD4 and 
anti-CD8 antibodies were purchased from Caltag Laboratories.  Cells 
were analyzed on a flow cytometer (Epics Profile II; Coulter, Hia- 
leah, FL). 
Mtv-7 Southern Hybridization and SSR Mapping.  Genomic liver 
DNA was isolated  as described (27). Eco RI-digested  genomic  DNA 
was analyzed by Southern hybridization for the presence of Mtv-7 
as described (28). 
DIMit16 and DIMit56 primers were purchased from Research 
Genetics (Huntsville, AL). PCR was performed according to the 
specifications of the GeneAmp PCR reagent kit (Perkin-Elmer 
Cetus, Norwalk, CT) with the following modifications. 20 ng of 
genomic liver DNA was used in each 9-#1 PCR reaction mixture 
containing lx reaction  buffer,  0.1 #1 of each primer (6.6 #M stock), 
and 0.025 #1 [c~-~2p]dCTP (3,000 #Ci/mmole; New England Nu- 
clear, Boston, MA). Samples were first run on a programmable 
thermal controller (PTC-100; MJ Research, Inc., Boston, MA) ac- 
cording to the GeneKeleaser  (BioVentures, Inc., Murfreeshoro,  TN) 
thermocycling protocol. 1 #1 of AmpliTaq  DNA polymerase  con- 
taining 0.05 U was then added to each sample, and the reaction 
mixtures were amplified  using the thermocycling  protocol described 
by Dietrich et al. (29). Samples were run on a 7% acrylamide- 
formamide gel (30). Reaction products were visualized  by autora- 
diography. 
Isolation of  Polyoma Virus-specific Y Cells.  Newborn C57BK/cdJ 
mice were injected subcutaneously in footpads with 1-5  x  l0  s 
PFU of virus. At 8-13 d of age, 1 x  106 mononuclear cells from 
draining popliteal and inguinal lymph nodes were cocultured with 
10  ￿  106 stimulator cells per well in 24-well cluster plates (Costar 
Corp., Cambridge, MA) in 2 ml of Iscove's modified Dulbecco's 
medium containing 10% Rat T-Stim without Con A (Collabora- 
tive Research, Bedford, MA),  10% heat-inactivated fetal bovine 
serum, 4 mM glutamine, and 50 #M 2-mercaptoethanol  (complete 
medium). Stimulator cells were C57BR/cdJ spleen cells infected 
with A2 virus (multiplicity of  infection = 0.01) for 24 h, and then 
given 2,000 fads of y-radiation. Viable mononuclear cells were re- 
stimulated at day 10 and used at day 6-8 of culture for cytotoxicity 
assays and cytofluoromettic analyses. 
Isolation of TILs.  A 5-wk-old C57BR/cdJ male inoculated at 
birth with A2 virus was injected subcutaneously with 13  x  106 
cells of the C57BK/cdJ polyoma tumor cell line (see above). 15 d 
later, the tumor was resected, minced, and digested with 500 U/ml 
coUagenase (ICN Biomedicals, Inc., Costa Mesa, CA) for 1 h at 
37~  Nonadherent cells were collected following two rounds of 
incubation in plastic petri dishes (Nunc, Roskilde, Denmark) for 
1 h at 37~  and 7% CO2. Viable mononuclear cells were isolated 
on LSM (Organon Teknika, Durham,  NC), incubated for 16 h 
at 37~  and 7% COz in complete medium, then stained and ana- 
lyzed by cytofluorometry. No differences in CD4,  CD8, or V/3 
expression were found between T cells analyzed  immediately after 
isolation from either the polyoma tumor or normal C57BK/cdJ 
lymph nodes and those analyzed  following 16-h incubation in com- 
plete medium (data not shown). These TILs were established as 
a line by weekly passage with virus-infected,  irradiated  C57BR/cdJ 
spleen cells for 8 wk. 
Cytotoxicity  Assays.  The  CytoTox 96  nonradioactive assay 
(Promega, Madison, WI) was used with TCMK-1 (H-2  k) target 
cells (American Type Culture Collection, Kockville,  MD) to assay 
cytotoxic activity by the tertiary culture of polyoma-immune T 
cells (see Fig. 3). The assay  was carried out according to manufac- 
turer's directions using 1 x  104 TCMK-1 cells per well of 96-well 
U-bottom  microtiter plates, except that the assay medium was 
phenol red-free  AIM V medium (GIBCO BRL, Gaithersburg, MD). 
TCMK-1 cells were either left uninfected or infected with virus 
(multiplicity of infection =  10) for 20 h before use in the assay. 
Spontaneous release of lactate dehydrogenase  was *10% for unin- 
fected and infected cells over a 4-h assay at 37~  and 7% CO2. 
To assay cytotoxic activity by the TIL line (see Fig. 5), SlCr- 
release assays were performed as described  by Gooding (31), using 
C57BR/cdJ polyoma tumor cells and SV40-transformed (H-2  k) 
PSC3H cells as targets. These target cells were incubated with 100 
U/ml recombinant  mouse interferon-'y  (Genzyme,  Cambridge, MA) 
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16% for PSC3H cells and 26% for polyoma tumor cells over a 
6-h assay at 37~  and 7% CO2. 
Percent specific lysis for each assay was determined from qua- 
druplicate samples. Standard errors of the mean value were always 
<5% of mean values and are omitted. 
Results 
Resistance of the C57BR/cdJ Mouse to Polyoma Tumors Has 
an Immunological Basis.  C57BK/cdJ mice are pyvS-negative 
and highly resistant to tumors induced by polyoma virus, 
while C3H/BiDa mice are PyvS-positive and highly suscep- 
tible. Despite this difference, neonatally infected mice of  both 
strains develop disseminated infections, and cells from the resis- 
tant C57BR/cdJ mouse are readily transformed by polyoma 
T  antigens in vitro (14). It thus appears that Pyv  s is not es- 
sential for replication or transformation by the virus, but rather 
acts in some systemic manner to allow development of  tumors. 
One model consistent with these observations is that Pyv  s 
acts  to prevent  an effective immune response  to polyoma 
tumors.  Such a model would imply that the resistance  of 
C57BK/cdJ mice has an immunological basis and that these 
mice would become susceptible if immunosuppressed.  Results 
shown in Table  1 confirm this expectation. 
Tumors developed in 100% of adult C57BK/cdJ mice ir- 
radiated before virus inoculation, while the same dose of  virus 
induced tumors in less than 5%  of unirradiated newborn 
C57BK/cdJ mice.  This difference is due to irradiation and 
not to the age difference between the two groups, since new- 
born mice of even the most susceptible  strains  are known 
to become resistant as adults (7,  32).  Irradiated mice uni- 
formly developed bilateral salivary gland tumors at 7-8 wk 
postinfection; mammary gland tumors, thymic epitheliomas 
and an ameloblastoma were also seen in this group of animals. 
Peripheral blood smears taken at necropsy showed severe leu- 
kopenia, and immunobtots of tumors were clearly positive 
for viral T antigens and capsid proteins, confirming that the 
tumors arose  in immunosuppressed hosts and were virus- 
induced. 
The two positive animals in the nonirradiated group each 
developed a single gross tumor. This contrasts with the de- 
velopment of multiple gross tumors per animal typically seen 
in PyvS-positive mouse strains  such as C3H/BiDa (8,  33). 
These C57BR/cdJ tumors, both of mammary gland origin, 
were composed of sheets of spindle-shaped  cells and differed 
histologically from the comedo-type intraductal carcinoma 
typically seen in C3H/BiDa mice (34).  It seemed possible 
that these unusual tumors arising in immunocompetent mice 
were variants that somehow escaped immunosurveillance. To 
test this possibility, the tumors were injected subcutaneously 
into adult C57BK/cdJ mice that had been inoculated at birth 
with polyoma virus. Both tumors transplanted readily to these 
polyoma-immune hosts, indicating that they were indeed im- 
mune escape variants.  As a control, a tumor that arose in 
an irradiated C57BK/cdJ mouse (and was therefore not sub- 
ject to immune selection) was tested; this tumor was rejected 
by polyoma-immune C57BR./cdJ mice as expected, but did 
Table  1.  Immunological  Resistance of C57BR/cdJ Mice 
a. Effects  of irradiation  on the tumor response of C57BR/cdJ mice* 
Unirradiated  Irradiated 
t 
Fraction of  2/47  17/17 
mice with 
tumor(s) 
b.  Transplantation properties of tumors  arising in unirradiated 
and irradiated C57BR/cdJ  mice* 
Fraction of 
polyoma-immune 
mice developing 
Tumor Donor  tumor 
Unirradiated C57BR/cdJ  4/4 
Unirradiated C57BR/cdJ  5/5 
Irradiated C57BR/cdJ  0/8 
" Unirradiated  C57BK/cdJ  mice were inoculated  at birth with polyoma 
virus. Adult C57BK/cdJ  mice were "),-irradiated  (800-900 rads) and in- 
oculated  with polyoma  virus 24 h later. Mice were necropsied  when mori- 
bund, or at 6 mo after  infection,  and tissue sections  examined  histologically. 
Adult C57BR/cdJ mice that had been inoculated  with polyoma  virus 
at birth were injected subcutaneously  with minced tumor suspensions. 
Tumors from both of the unirradiated and from one of the irradiated 
polyoma-infected  C57BR/cdJ  mice  (a) were maintained  by serial  passage 
in C57BK/cdJ mice before transplantation. Mice were scored for gross 
tumors 2 wk after transplantation. 
transplant readily to nonimmune C57BR/cdJ mice.  These 
results show that the C57BK/edJ mouse is capable of  mounting 
an effective immune response  to polyoma tumors, and that 
rare tumors which arise in this strain are variants that escape 
immune recognition. 
Tumor Susceptibility and  Mtv-7  Cosegregate in  Backcross 
Mice.  Given  that  Pyv  s  determines  susceptibility  in  F1 
hybrids between C3H/BiDa and C57BK/cdJ mice, it must 
act in some way to negate the immune response contributed 
by the C57BK/cdJ parent.  We hypothesize that Pyv  s en- 
codes an Mtv SAG that deletes T  cells required for protec- 
tion  against  polyoma  tumors.  Comparison  of  the  Mtv 
proviruses  carried by these strains  suggests two candidates, 
Mtv-6 and Mtv-7, based on their presence in C3H/BiDa and 
absence in C57BK/cdJ mice (Table 2). Mtv-17 is not consid- 
ered because a mutation in its LTR most likely prevents ex- 
pression (45), and no deletion of T cells bearing the expected 
V/3 specificity has been found (44). Anti-polyoma T cells in 
the resistant C57BK/cdJ mouse would therefore be predicted 
to express either V/33 if Pyv  s were Mtv-6 sag, or VB6 and/or 
V/37 if Pyv  s were Mtv-7 sag. Expression of other VB do- 
mains targeted by Mtv-6 sag (V/35) or Mtv-7 sag (V/38.1 and 
V/39) is excluded since the coding regions for these segments 
are absent from the germline in C57BK/cdJ mice (37). 
To determine if tumor susceptibility cosegregates with ei- 
ther Mtv-6 or Mtv-7, 35 backcross (F1  x  C57BK/cdJ) mice 
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Mtv Provirus  C3H/BiDa  C57BR/cdJ  Vfl Deletion  References 
6(16)  +  -  3,  5  38,  39 
7(1)  +  -  6,  7,  8.1,  9  40 
8(6)  +  +  11,  12  41 
9(12)  +  +  5,  11,  12  41-43 
11(14)  -  +  11,  12  41,  42 
14(4)  +  +  ? 
17(4)  +  -  none  44 
29(6)  -  +  ? 
Mtv provirns distributions in C3H/BiDa and C57BR/cdJ mice are taken from Frankel et al. (28), Kozak et al. (35), and Scherer et al. (19). Numbers 
in parentheses indicate chromosomal locations of Mtv provirnses (35, 36). Bold-faced Vfls are encoded in germlines of both C3H/BiDa and C57BR/cdJ 
mice; genes of all other listed Vfls are deleted in C57BR/cdJ mice (37). 
were examined for  V~/usage in their peripheral T  cells by 
cytofluorometry using absence of V~/3 and VB6 as markers 
for Mtv-6 and Mtv-7, respectively. The same mice were also 
typed for Mtv-7 by Southern hybridization. Of 18 mice which 
failed to develop tumors, 15 had high levels of V/56 + T  cells, 
similar to the levels seen in C57BR/cdJ mice; none of these 
animals inherited the Mtv-7 provirus (Table 3). Conversely, 
15  of  17  mice  which  developed  tumors  deleted  Vfl6 +  T 
cells, as in C3H/BiDa mice; all 15 of these animals inherited 
Mtv-7. No correlation was seen between Vfl3 usage and pres- 
ence or absence of tumors (Table 3). Thus, in 30 of 35 mice, 
the presence (or absence) of tumors was correlated with the 
Table  3.  Correlation of Vfl Usage, Inheritance of Mtv-7,  and Susceptibility to  Tumors in Backcross Mice 
Tumor-free  Tumor-bearing 
V~/3  Vfl6  Mtv-7  Vfl3  V/36  Mtv-7 
0  19  -  0  1  + 
0  18  -  0  0  + 
0  20  -  0  1  + 
0  19  -  0  1  + 
1  17  -  0  1  + 
9  18  -  1  2  + 
4  17  -  6  2  + 
7  19  -  6  1  + 
7  17  -  6  1  + 
6  19  -  5  2  + 
nd  16  -  7  0  + 
nd  18  -  7  0  + 
nd  18  -  5  1  + 
nd  18  -  7  0  + 
nd  14  -  6  1  + 
nd  1  +  0  21  - 
10  1  +  9  20  - 
11  3  + 
V/~ expression by splenic T cells from 35 (C3H/BiDa  x  C57BR/cdJ)  x  C57BR/cdJ backcross mice inoculated at birth with polyoma virus was 
determined by cytofluorometric  analysis. Values are %  total o~B-T cells expressing either VB3 or VB6. nd indicates not determined.  As reference, 
values for the parental  strains are: for VB3,  1.0  _+ 0.6 in C3H/BiDa and 7.0 +_  1.2 in C57BR/cdJ; and for Vfl6,  0.3  _+ 0.3 in C3H/BiDa and 
16.2  _+ 0.8 in C57BR/cdJ.  Results of Mtv-7 genotyping by Southern hybridization are given for each animal. 
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showed the expected concordance between inheritance of  Mtv-7 
and absence of V36 + T  cells, but were dearly nonconcor- 
dant with respect  to Mtv-7 and tumor phenotype. 
The analysis was extended to an additional 84 backcross 
mice which were typed for Mtv-7.  The combined data for 
all 119 mice are presented in Table 4. The association between 
Pyv  s  and  Mtv-7  is  highly  significant,  with  102  animals 
(86%) showing concordance between Mw-7 and Pyv  s. Chi- 
square  analysis gives a probability of << 0.005  that these 
results would arise by chance,  assuming no association be- 
tween these genes.  17 backcross  mice (14%) were noncon- 
cordant. Eight of these were Mtv-7- but tumor-bearing. In- 
terestingly, only single tumors were found in these mice, as 
was the case with the rare  C57BR/cdJ parental mice that 
developed  tumors. This contrasts with the majority of the 
Mtv-7 + backcross  mice which developed  multiple tumors 
(Table 4). The finding of 14% nonconcordant mice raises two 
possibilities:  (a) Pyv  s and Mtv-7 sag are separate but linked 
genes,  or (b) Pyv  s is identical to Mw-7 sag,  and incomplete 
penetrance or other mitigating factors are involved. 
Pyv  s and Mtv-7 Show No Evidence of Recombining.  IfPyv  s 
and Mw-7 sag are linked genes, then the nonconcordant back- 
cross mice would be expected to have inherited a recombinant 
chromosome 1 from their F1 parent.  To test this directly, 
simple sequence repeat (SSR) polymorphisms (29) were sought 
as markers to detect recombination on either side of Mtv-7. 
SSR probes known to map to the distal region of chromo- 
some 1 (map obtained from Research Genetics, Inc., Hunts- 
ville,  AL)  were  screened,  and  two  appropriate  markers 
identified. 
The DNAs from 110 backcross  mice were typed for the 
SSR markers by PCIL and for Mtv-7 by Southern hybridiza- 
tion. Based on their frequencies of recombination with Mtv-7, 
the SSR markers are located '~10 cM on either side of the 
provirus (Fig. 1). Significantly, the fraction of mice that was 
recombinant in each of these intervals was roughly the same 
for the nonconcordant and concordant groups, i.e.,  in the 
range of 6-12% (Table 5). These results do not support the 
possibility that Pyv  s and Mtv-7 are separate genes, since this 
would require that the nonconcordant mice show a much 
higher frequency of recombination ('~70% if the genes were 
14 cM apart) in one of the two intervals. 
Table  4.  Association  of Mtv-7 with Development of Tumors in 
Backcross Mice 
Backcross mice 
Mtv-7  Tumor-bearing  Tumor-flee 
+  63 (73%)  9 
-  8  (0%)  39 
119 (C3FI/BiDa x  C57BR/edJ) x  C57BR/cdJ  backcross mice were 
genotyped  for Mtv-7 by Southern hybridization.  Numbers in parenthe- 
sis indicate % mice with multiple tumors. 
Figure 1.  Mapping  of  D1Mitl6 
and DIMit56 SSIks with respect 
to Mtv-7 on chromosome  1. 110 
(C57BR./cdJ x C3H/BiDa)F1 x 
C57BR./cdJ backcross mice  were 
typed for presence of Mtv-7 and 
for D1Mit16 and D1Mit56 SSR 
polymorphisms.  Autoradiogtaphs 
show length polymorphisms  of 
these SSRs for parental and F1 
mice. Numbers indicate  location 
(in cM) of  D1Mit16, D1Mit56  and 
Mtv-7 on chromosome 1, based 
on the  Jackson  Laboratory  genetic 
map placing Mtv-7 at 75.0 cM. 
V~6 Is  Used Preferentially by Polyoma-specific T  Cells.  If 
Pyv  s is Mtv-7 sag,  then its action in determining suscepti- 
bility to polyoma tumors is expected to be based on the elimi- 
nation of T cells bearing either V36 or V37 domains. Like- 
wise, resistance in the C57BR/cdJ mouse should be mediated 
by T  cells bearing one, or possibly both,  of these V3 do- 
mains. To test this prediction, T cells taken from lymph nodes 
of polyoma virus-infected C57BR/cdJ mice were stimulated 
twice in vitro with virus-infected,  irradiated syngeneic spleen 
cells, and then analyzed for V3 usage as well as for expres- 
sion of CD4 and CD8.  As shown in Fig.  2,  the majority 
of these  T  cells  expressed  V36  (76%)  and  were  CD8 + 
(95%);  no other V3 type was elevated,  including V37.  T 
cells from lymph nodes of normal C57BR/cdJ mice were only 
15%  V36 §  This experiment was repeated with  separate 
cultures from eight C57BR/cdJ mice, with the same general 
results. VB6-usage ranged from 33 to 100%, while usage of 
V3s 2, 3, 7, and 14 remained low (~<10%). A tertiary cul- 
ture composed of >98% CD8 +  V36 + T cells lysed polyoma 
virus-infected but not uninfected H-2  k target cells (Fig. 3). 
Biased usage of V36 was also observed in polyoma tumor- 
Table  5.  Recombination  Analysis of Backcross Mice 
Recombination frequencies 
between Mtv-7 and flanking SSRs 
Backcross Mice  DIMit16  D1Mit56 
Concordant  8.6%  (8/93)  10.8%  (10/93) 
Nonconcordant  11.8%  (2/17)  5.9%  (1/17) 
110 (C3H/BiDa x C57BIk/cdJ) x C57BR/cdJ  backcross mice inocu- 
lated at birth with polyoma  virus were scored  for tumors  and their  DNAs 
genotyped for Mtv-7 and SSR polymorphisms.  Concordant  mice were 
either Mtv-7  + and tumor-bearing, or Mtv-7- and tumor-free. Noncon- 
cordant mice  were either Mtv-7  + and tumor-free,  or Mtv-7- and tumor- 
bearing. 
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Figure  2.  Polyoma virus-specific  T cells are predominantly V36 + and 
CD8 +  . T cells from polyoma virus-immune C57BR/cdJ lymph node cells 
were stimulated twice in vitro with virus-infected, irradiated C57BR/cdJ 
spleen cells. T cells from inguinal lymph nodes pooled from four C57BR/cdJ 
mice served as controls. T cells were indirectly stained with monoclonal 
antibodies to o~/~-TCR and to the indicated V3 specificities, or directly 
stained with PE-conjugated anti-CD4  and PE-conjugated anti-CD8. 
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Figure  4.  Vfl6 usage by T cells infiltrating a polyoma tumor.  TILs 
recovered from  a  C57BR/cdJ-derived polyoma tumor in  a  polyoma 
virus-immune C57BR/cdJ host were indirectly stained with monoclonal 
antibodies to the ~3-TCR or to V36; anti-VlO6-stained  cells were double- 
labeled with PE-anti-CD4 or PE-anti-CD8 antibodies. Cells were quan- 
titated by cytofluorometry.  Data are presented as log fluorescence  intensity. 
Numbers are % c~3-T cells. 
usage  of V36  by  polyoma-specific  CTLs  in  the  resistant 
C57BR/cdJ mouse, and support the conclusion that Pyv  s is 
indeed Mtv-7 sag acting to delete V36 + T  cells in the  sus- 
ceptible  C3H/BiDa  mouse. 
infiltrating  lymphocytes  (TILs),  as follows.  A  C57BR/cdJ 
mouse immunized at birth with virus was injected subcutane- 
ously with a large dose (13  x  106) of cells from a polyoma 
tumor that arose in an irradiated C57BR/cdJ animal (see Table 
1  b).  Two  weeks  later,  the  tumor  was  harvested  and  the 
infiltrating T cells were recovered and analyzed. Roughly 80% 
of the TILs were CD8 +  and nearly half of these expressed 
V~6  (Fig.  4).  In  contrast,  only  14%  of CD4 +  TILs  ex- 
pressed V36.  A  line was established from TILs by repeated 
passage in vitro in the presence of infected, irradiated stimu- 
lator cells.  This line,  containing  >95%  CDS+Vfl6 +  cells, 
exhibited cytolytic activity against C57BR/cdJ polyoma tumor 
cells  but  not  against  an  SV40-transformed  H-2  k cell  line 
(Fig. 5). These results confirm the expectation of preferential 
Discussion 
The  polyoma  tumor  susceptibility  gene  Pyv  s  acts  by 
preventing the host from mounting an effective immune re- 
sponse to virus-induced tumors. In a majority of mice from 
a  cross  in  which  Pyv  s  and  the  mouse  mammary  tumor 
provirus Mtv-7 are segregating, tumor development cosegre- 
gates with the provirus.  The known role of Mtv-7 SAG in 
deleting V~6 + T  cells provides a plausible mechanism of ac- 
tion for Pyv  s. 
We have argued against the possibility of linkage and in 
favor  of  identity  between  Pyv  s  and  Mtv-7  sag  on  two 
grounds.  The first is genetic, based on the fact that pheno- 
typically nonconcordant backcross mice-those that are either 
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CD8 + VB6 + T cells possess polyoma virus-specific  cytotoxic  Figure  3. 
activity. An in vitro tertiary culture of polyoma virus-immune C57BR./cdJ 
cells derived as in Fig. 2 and composed of >98% CD8 + V36 + T cells, 
was assayed  for lytic activity against uninfected (-O-) and polyoma virus- 
infected (--~-) H-2  k target cells. 
Figure  5. 
Or 
i  i  ,iw 
10:1  5:1  1:1 
Effector:Target Ratio 
Specific lysis of polyoma tumor cells by a CD8 +  VB6 + TIL 
L 
line. A TIL-derived  T cell line composed of >95% CD8+V36 + T cells 
was assayed for lytic activity against slCr-labeled C57BR/cdJ polyoma 
tumor cell (A) and slCr-labeled SV40-transformed H-2  k cells (--O-). 
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not selectively recombinant in the region of chromosome 1 
flanking Mtv-7. Recombinant backcross mice were found at 
equal frequencies in the nonconcordant and concordant groups, 
and not preferentially in the former group as would be ex- 
pected  if Pyv  s  and Mtv-7  were  separate  linked  genes.  The 
second is immunological, and is based on deletion of V/~6 § 
T cells by Mtv-7 sag in the susceptible C3H/BiDa mouse cou- 
pled with strongly biased usage of V/36 by polyoma-specific 
T  cells  in  the  resistant  C57BR/cdJ  mouse.  T  cells  from 
polyoma-primed C57BR/cdJ mice stimulated in vitro, as well 
as those recovered from a polyoma tumor carried in a virus- 
immune C57BR/cdJ host, are predominantly CD8+V~6 + . 
These cells  possess  virus-specific cytolytic activity. 
Several  factors may be cited to explain the appearance of 
nonconcordant mice,  all  consistent  with Pyv  s being Mtv-7 
sag.  Approximately  7%  of backcross mice were  scored  as 
tumor-free through they clearly inherited Mtv-7. These mice 
can be explained, at least in part, by the fact that Pyv  s is less 
than 100% penetrant;  in repeated experiments with groups 
of '~30 C3H/BiDa mice, the frequency of tumor induction 
is between  95  and  100%.  In addition,  the chance of mis- 
phenotyping backcross mice as tumor-free is elevated because 
the average number of tumors per affected animal,  termed 
the tumor frequency index (TFI), is lower in these mice com- 
pared to (C3H/BiDa  x  C57BR/cdJ)F1 mice. The TFI for 
backcross mice was 2.9 (131 tumors among 45 mice) and for 
F1 mice 4.6 (207 tumors among 45 mice). There could also 
be other effects attributed  to the C57BR/cdJ genetic back- 
ground which might,  for example,  cause a slower deletion 
of T cells by Mtv-7 sag. Delayed T cell deletion by an endog- 
enous superantigen may allow specific antigen to block dele- 
tion of antigen-specific T  cells bearing superantigen-reactive 
V~  domains  (46).  Any or all  of these  factors could result 
in  the  failure  of Mtv-7 +  backcross  mice  to  be  scored  as 
tumor-bearing.  With respect  to the  7%  of backcross mice 
which developed tumors without inheriting Mtv-7, the most 
plausible explanation is that these tumors represent immune 
escape  variants  as  has  been  shown  for the  rare  tumors  in 
C57BR/cdJ mice (Table 1). This interpretation is supported 
by the fact that only single tumors were found in these non- 
concordant backcross mice (Table  4). 
While  the  identification  of Pyv  s  as  Mtv-7  sag  has  been 
based on analyses of crosses between C3H/BiDa and C57BR/ 
cdJ mice, additional support comes from the known distri- 
butions of Mtv proviruses and polyoma tumor susceptibili- 
ties among other mouse strains.  Historically (7) and in our 
own hands  (13),  mice possessing the highest  susceptibility 
to tumor induction by polyoma all possess the H-2  k haplo- 
type. Not all H-2  k mice are highly susceptible,  however. As 
shown in Table 6, the correlation of high susceptibility with 
Mtv-7 and with no other Mtv provirus is clear.  The combi- 
nation  of H-2  ~ and Mtv-7  as interactive  codeterminants  of 
susceptibility  also  reflects  the  hierarchy of presentation  of 
Mtv-7 SAG by class II MHC molecules of different haplo- 
types:  k  >  d  >  b  >  >  q  (22,  47). 
Our  results  implicate  CD8+V/36+CTL  as  critical  anti- 
polyoma effector T  cells  in H-2  k Mtv-7-  mice inoculated 
with  virus  as  newborns.  However,  H-2  k  Mtv-7 +  mice, 
which are susceptible as newborns, are known to develop re- 
sistance  soon  after  birth  (7).  This  implies  that  non-V~6- 
bearing T  cells are involved in polyoma tumor immunity in 
C3H/BiDa  mice inoculated  as young adults. 
Most Mtv SAGs, including Mtv-7 SAG, negatively select 
CD8 + as well as CD4 + thymocytes despite the requirement 
for association of Mtv SAGs with class II MHC  molecules 
(23).  Clonal deletion of CD4 +  CD8 + thymocytes has been 
put forward to explain Mtv SAG-mediated deletion of VB- 
Table  6.  Polyoma Tumor Susceptibility of 1-1-2  ~ Mouse Strains Correlates with  the Presence of Mtv-7 
Mtv Proviruses 
Strain  Susceptibility  1  3  6  7  8  9  11  14  17  23  29  30 
C3H/BiDa  high  -  -  +  +  +  +  -  +  +  -  -  - 
C58  high  -  +  -  +  ....  +  -  -  + 
CBA/J  high  -  -  +  +  +  +  -  +  +  -  -  - 
AKR  high  -  -  -  +  +  +  -  -  +  +  -  + 
RF/J  high  +  -  -  +  +  -  -  -  +  +  +  + 
C57BR/cdJ  low  ....  +  +  +  +  -  -  +  - 
C3H/HeJ  low  +  -  +  -  +  -  +  +  .... 
CBA/CaJ  low  ....  +  +  -  +  .... 
B10.BR  low  ....  +  +  -  -  +  -  -  + 
BALB.K  low  -  -  +  -  +  +  ...... 
The distribution of Mtv proviruses are taken from Frankel et al. (28), Ignatowicz et al. (44), Kozak et al. (35), Pullen et al. (39), and Scherer et 
al.  (19). High susceptibility strains have a >95%  tumor incidence and develop multiple tumors of diverse types; low susceptibility strains have a 
lower tumor incidence and generally develop single tumors per animal (7,  13, and unpublished data). 
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finding that  Mtv-7 + mice expressing a transgene encoding 
a class I MHC-restricted  V38.1-TCR delete mature single 
CD8 + but not CD4+CD8 + thymocytes indicates that Mtv-7 
SAG can act in thymocyte maturation  at a point beyond the 
CD4+CD8 + stage (50).  In addition,  Mtv-7 + CD4-knock- 
out mice delete CD8 + T cells bearing V36, 8.1,  and 9, but 
not V37 which has the lowest affinity for Mtv-7 SAG (51), 
implying  that  CD4 expression may be required  for clonal 
deletion only when Mtv SAG-TCR affinity is low (52). 
In another system, a novel Mtv-SAG contributes to devel- 
opment of spontaneous B cell lymphomas in SJL mice. In 
this case,  the Mtv-SAG stimulates CD4+V316 + T  cells to 
release cytokines required for tumor growth (53, 54). While 
endogenous Mtv-SAGs are required for tumor development 
in both this and the polyoma system, the strategies are clearly 
different, involving stimulation of CD4 § T cells in one case 
and deletion  of CD8 + T  cells  in  the other. 
Biased usage of V36 by polyoma-specific CTL  suggests 
that these T  cells recognize few, and perhaps a single,  viral 
peptide(s) associated with a particular H-2  ~ class I molecule. 
A growing body of evidence demonstrates limited V3 as well 
as Voe domain usage by class I- and class II-restricted T cell 
clones and hybridomas recognizing  specific  antigen-MHC 
complexes (reviewed by Casanova and Maryanski [55],  and 
references therein).  The peptide(s) recognized by the V36 + 
anti-polyoma CTL are most likely derived from the MT and/or 
LT protein(s) of polyoma virus. Recombinant vaccinia viruses 
carrying MT or LT coding sequences as well as synthetic MT 
or  LT  peptides  immunize  rodents  against  transplanted 
polyoma-induced tumors (56, 57). Polyoma tumors invari- 
ably express MT, consistent with the essential role this pro- 
rein plays in cellular transformation  (58, 59), tumor induc- 
tion  (60),  and  virion  assembly (61).  LT is  also  generally 
expressed,  though  often in  a  truncated  form,  while viral 
capsid proteins  are either  not  expressed or expressed non- 
uniformly in  polyoma tumors  (25).  Because the polyoma 
tumor target cells used here (Fig. 5) express only T proteins, 
the latter must provide the TSTAs for the polyoma-specific 
CDS+V36 +  CTLs  in  C57BR/cdJ  mice  (Tables  3  and  5). 
Attempts are underway to identify the T  antigen peptide(s) 
recognized by these CTLs. 
The identification of Pyv  s as Mtv-7 sag represents a third 
manifestation of the function of this gene, having first been 
discovered as encoding the minor lymphocyte stimulating an- 
tigen Mls-1 a (28, 40). A number of interesting questions can 
be raised concerning the biological significance of these nones- 
sential but widely distributed proviral genes which encode 
superantigens.  Though  clearly a susceptibility factor vis-a- 
vis experimental  infection with  polyoma virus,  Mtv SAGs 
work in the opposite way, as determinants of resistance,  with 
respect to infection by exogenous Mtvs.  These viruses are 
lymphotropic  and depend on SAG-mediated T  cell activa- 
tion in their life cycle (62). Mice carrying a particular Mtv 
provirns undergo deletion of those T cells required for repli- 
cation by the homologous Mtv (63). While the presence of 
germline proviruses may reflect an evolutionary mechanism 
for protection against horizontal transmission of Mtvs, it also 
appears  to carry a potential risk of increasing susceptibility 
to unrelated infectious agents. A larger question concerns the 
possibility that  endogenous  superantigens  other than  Mtv 
SAGs exist,  and in species other than  the mouse, and that 
such genes may act in a similar manner to influence suscepti- 
bility to disease. 
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